Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, and the Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Curr Cardiol Rep. 2013 Jul;15(7):381. doi: 10.1007/s11886-013-0381-3.
Arterial thrombosis is a major component of vascular disease, especially myocardial infarction (MI) and stroke. Current anti-thrombotic therapies such as warfarin and clopidogrel are effective in inhibiting cardiovascular events; however, there is great inter-individual variability in response to these medications. In recent years, it has been recognized that genetic factors play a significant role in drug response, and, subsequently, common variants in genes responsible for metabolism and drug action have been identified. These discoveries along with new diagnostic targets and therapeutic strategies hold promise for more effective individualized anti-coagulation and anti-platelet therapy.
动脉血栓形成是血管疾病的主要组成部分，尤其是心肌梗死（MI）和中风。目前的抗血栓治疗药物，如华法林和氯吡格雷，在抑制心血管事件方面是有效的；然而，这些药物的反应在个体之间存在很大的差异。近年来，人们已经认识到遗传因素在药物反应中起着重要作用，随后，与代谢和药物作用相关的基因中的常见变异也被确定。这些发现以及新的诊断靶点和治疗策略有望为更有效的个体化抗凝和抗血小板治疗提供帮助。
